Search
Lanatoside C
go.drugbank.com/drugs/DB13467InvestigationalCategories: lanatoside CSynonyms: Lanatoside CPerampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalThe FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-oneAlitretinoin
go.drugbank.com/drugs/DB00523ApprovedTretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. … An important regulator of gene expression during growth and development, and in neoplasms.
Mixtures: Clindamycin 1% / Niacinamide 4% / Tretinoin 0.05%Categories: Vitamin A, P-glycoprotein substratesAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID RATIO 1 MG, Anagrelid Nordic 1 mg TablettenMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: CELSENTRI® 150 MG, CELSENTRI® 300 MGCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise … 2 diabetes mellitus [L5897], [FDA label].
Mixtures: VOKANAMET ® TM_TABLETAS RECUBIERTAS 150/1000 MG, VOKANAMET 50 MG/500 MGCategories: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors, Drugs Used in DiabetesDanazol
go.drugbank.com/drugs/DB01406ApprovedInvestigationalA synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. … Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: CIPLADANOGEN® 200 MG CAPSULAS, DANAZOL 100 MGMicafungin
go.drugbank.com/drugs/DB01141ApprovedInvestigationalIt belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. … Micafungin is an antifungal drug.
Products: Micafungin in Sodium Chloride, Micafungin In 0.9% Sodium Chloride InjectionFluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalFluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. … Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: VERLIN TABLETAS X 50 MG, VOXAMIN® TABLETA RECUBIERTAVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Categories: Heterocyclic Compounds, 2-Ring, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MG, ZELBORAF 240 MG FILM KAPLI TABLET ,56 FILM KAPLI TABLET